Key Takeaways:
Alebund Pharmaceuticals passed its HKEX listing hearing, with revenue surging nearly 3.7 times to RMB 30.6 million in the year ended Dec 31, 2025.
The biopharmaceutical company, which develops kidney disease therapies, recorded a loss of nearly RMB 752 million for the period, widening from RMB 335 million in 2024. Alebund raised approximately RMB 2 billion across multiple financing rounds, drawing investors including Tencent Holdings Ltd. and Singapore sovereign wealth fund GIC.
Tencent currently holds an 11.73 percent pre-IPO stake in the company. Jefferies, BofA Securities and Huatai International are acting as joint sponsors for the listing on Hong Kong's Main Board.
The hearing clearance moves Alebund one step closer to a Hong Kong debut, though the company has not yet disclosed the offer price, deal size or target listing date. The pricing will determine its enterprise value relative to listed kidney disease therapy peers.
The clearance positions Alebund to tap Hong Kong's equity market for growth capital. Investors will watch for the offer price and deal size in the coming weeks to gauge institutional demand for the kidney disease therapy specialist.
This article is for informational purposes only and does not constitute investment advice.
